Deep Pharm-Chem Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 05-12-2024
- Paid Up Capital ₹ 0.55 M
as on 05-12-2024
- Company Age 33 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.20 Cr
as on 05-12-2024
- Revenue 7.77%
(FY 2022)
- Profit -17.63%
(FY 2022)
- Ebitda -16.22%
(FY 2022)
- Net Worth 17.16%
(FY 2022)
- Total Assets 7.43%
(FY 2022)
About Deep Pharm-Chem
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.55 M.
The company currently has active open charges totaling ₹1.20 Cr.
Nitin Shah, Varsha Shah, Ramesh Hansora, and One other member serve as directors at the Company.
- CIN/LLPIN
U24139MH1991PTC062007
- Company No.
062007
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jun 1991
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Deep Pharm-Chem Private Limited offer?
Deep Pharm-Chem Private Limited offers a wide range of products and services, including Industrial Chemicals & Supplies, Chemical Intermediates.
Who are the key members and board of directors at Deep Pharm-Chem?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramesh Hansora  | Director | 04-Jan-2023 | Current |
| Nitin Shah | Director | 04-Jan-2023 | Current |
| Varsha Shah | Director | 07-Jun-1991 | Current |
| Navin Harsora | Director | 15-Oct-1996 | Current |
Financial Performance of Deep Pharm-Chem.
Deep Pharm-Chem Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 7.77% increase. The company also saw a substantial fall in profitability, with a 17.63% decrease in profit. The company's net worth Soared by an impressive increase of 17.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Deep Pharm-Chem?
Unlock access to Deep Pharm-Chem's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Yes Bank Limited Creation Date: 22 Mar 2012 | ₹6.00 M | Open |
Yes Bank Limited Creation Date: 31 Jan 2012 | ₹6.00 M | Open |
How Many Employees Work at Deep Pharm-Chem?
Unlock and access historical data on people associated with Deep Pharm-Chem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Deep Pharm-Chem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Deep Pharm-Chem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
